Carlyle Group Amends Adicet Bio Stake on Jan 25 Event

TL;DR

**Carlyle Group just updated its Adicet Bio stake, watch for market reaction!**

AI Summary

Carlyle Group Inc. filed an amended Schedule 13D/A on February 7, 2024, indicating a change in their beneficial ownership of Adicet Bio, Inc. common stock. The filing, triggered by an event on January 25, 2024, updates previous disclosures regarding Carlyle's stake in the pharmaceutical company. This matters to investors because it signals a potential shift in a major institutional investor's position, which could influence market perception and the stock's future performance.

Why It Matters

Changes in significant institutional holdings like Carlyle's can signal confidence or concern in a company, potentially impacting Adicet Bio's stock price and investor sentiment.

Risk Assessment

Risk Level: medium — A change in a major investor's position can introduce volatility and uncertainty for Adicet Bio's stock.

Analyst Insight

A smart investor would monitor Adicet Bio's stock performance and trading volume in the days following this filing to gauge market reaction to Carlyle's updated position, and potentially research the specific nature of the change in ownership (e.g., increase or decrease) if further details become available.

Key Players & Entities

• Carlyle Group Inc. (company) — the filing person and a major investment firm
• Adicet Bio, Inc. (company) — the subject company whose securities are being reported
• Jeffrey Ferguson (person) — authorized to receive notices for The Carlyle Group
• January 25, 2024 (date) — date of the event requiring the filing
• February 7, 2024 (date) — date the SC 13D/A was filed
• $0.0001 (dollar_amount) — par value per share of Adicet Bio common stock

Forward-Looking Statements

• Adicet Bio's stock price may experience short-term volatility as investors react to the updated ownership information from Carlyle Group. (Adicet Bio, Inc.) — medium confidence, target: 2024-03-07
• Other institutional investors will review Carlyle's updated position, potentially influencing their own investment decisions in Adicet Bio. (Adicet Bio, Inc.) — medium confidence, target: 2024-04-07

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $2.40 — from the Issuer at a purchase price of $2.40 per share (the January 2024 PIPE). Abin

Filing Documents

• d682129dsc13da.htm (SC 13D/A) — 172KB
• d682129dex992.htm (EX-99.2) — 12KB
• 0001193125-24-026734.txt ( ) — 186KB

of the Schedule 13D is hereby amended and supplemented as follows

Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On January 25, 2024, Abingworth Bioventures 8 LP purchased 833,333 shares of Common Stock in a private placement from the Issuer at a purchase price of $2.40 per share (the January 2024 PIPE). Abingworth Bioventures 8 LP purchased the Common Stock with its investment capital. Item4. Purpose of Transaction.

of the Schedule 13D is hereby amended and supplemented as follows

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: January 2024 PIPE

above

Item 3 above summarizes the January 2024 PIPE and is incorporated herein by reference. Item5. Interest in Securities of the Issuer.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 75,487,588 shares of Common Stock outstanding following the closing of the January 2024 PIPE, as disclosed in the Issuers prospectus supplement filed with the Securities and Exchange Commission on January 24, 2024. Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition The Carlyle Group Inc. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Holdings I GP Inc. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Holdings I GP Sub L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Holdings I L.P. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 CG Subsidiary Holdings L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 TC Group, L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Investment Management L.L.C. 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Carlyle Genesis UK LLC 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Abingworth LLP 3,060,292 4.1 % 0 3,060,292 0 3,060,292 Abingworth Bioventures 8 LP 3,060,292 4.1 % 0 3,060,292 0 3,060,292 The shares of Common Stock reported herein include (i) 2,986,292 shares of Common Stock held of record by Ab

of the Schedule 13D is hereby amended and supplemented as follows

Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit Number Description 1 Joint Filing Agreement (previously filed) 2 Power of Attorney.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : February 7, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures 8 LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory

View Full Filing

View this SC 13D/A filing on SEC EDGAR